Abstract
T cells have the capacity to eradicate diseased cells, but tumours present considerable challenges that render T cells ineffectual. Cancer cells often make themselves almost invisible to the immune system, and they sculpt a microenvironment that suppresses T cell activity, survival and migration. Genetic engineering of T cells can be used therapeutically to overcome these challenges. T cells can be taken from the blood of cancer patients and then modified with genes encoding receptors that recognize cancer-specific antigens. Additional genes can be used to enable resistance to immunosuppression, to extend survival and to facilitate the penetration of engineered T cells into tumours. Using genetic modification, highly active, self-propagating slayers of cancer cells can be generated. ? 2013 Macmillan Publishers Limited
Original language | English |
---|---|
Pages (from-to) | 525 - 541 |
Number of pages | 17 |
Journal | Nature Reviews Cancer |
Volume | 13 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2013 |